---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-26-000026"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:22:09.906692+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aurinia appoints Chair Kevin Tang as CEO; entire C-suite replaced effective March 23, 2026

## Summary
- Kevin Tang (Chair) appointed CEO, succeeding Peter Greenleaf; Greenleaf to consult for 3 months at $600/hr.
- Ryan Cole appointed COO ($300k salary, 50% bonus, 150k options); Michael Hearne appointed CFO (same terms).
- Departures: Peter Greenleaf, Matthew Donley (COO), Gregory Keenan (CMO), Joseph Miller (CFO) effective March 20-21.
- Thomas Wei appointed Chief Scientific Officer; Craig Johnson elected Lead Independent Director.
- Kevin Tang will receive no salary, bonuses, or equity for his CEO role.

## SEC filing metadata
- accession: 0001600620-26-000026
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000026/0001600620-26-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000026/auph-20260320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-26-000026
- JSON: https://secwatch.observer/filing/0001600620-26-000026.json
- Plain text: https://secwatch.observer/filing/0001600620-26-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.